Clinical Trial Update: DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial (RECAST) is re-evaluating eligibility criteria for active surveillance in ductal carcinoma in situ and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ

Snippet

Sponsor: QuantumLeap Healthcare Collaborative | Conditions: Ductal Carcinoma in Situ | Phase 2 | Status: RECRUITING